|
SRRK | Scholar Rock Holding Corp |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.07 |
| Leverage | 40.49% |
| Market Cap | $ 3.3B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -352.3m |
| Margin | -6980.61% |
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.